Efficacy of acetylleucine in vertigo and dizziness: a systematic review of randomised controlled trials

  • Paul VanderkamEmail author
  • Clara Blanchard
  • Florian Naudet
  • Denis Pouchain
  • Helene Vaillant Roussel
  • Marie Christine Perault-Pochat
  • Nematollah Jaafari
  • Rémy Boussageon



To assess the efficacy of acetylleucine to improve or stop an attack of vertigo and dizziness (vertigo/dizziness).


Systematic review by 2 independent reviewers. Consultation of the Medline, Cochrane and databases until September 2018. Keywords used: Acetylleucine, Tanganil®, Acetyl-DL-leucine, Acetyl-leucine. Trial selection: randomised controlled trials (RCTs) comparing acetylleucine against placebo.


Up until 2018, no RCTs have been published on the efficacy of acetylleucine in vertigo/dizziness.


There is no solid evidence of the efficacy of acetylleucine in vertigo/dizziness. Given its frequent prescription and the cost generated for the French social security system, high-quality randomised trials should be carried out to assess its efficacy.


Acetylleucine Dizziness Randomised controlled trial Treatment outcome Vertigo 


Contributions of authors

Paul Vanderkam performed the research, analysed the data and wrote the paper.

Clara Blanchard contributed to the writing of the paper and the data analysis.

Florian Naudet contributed to the writing of the paper.

Denis Pouchain contributed to the writing of the paper.

Marie-Christine Perrault-Pochat contributed to the writing of the paper.

Hélène Vaillant-Roussel contributed to the writing of the paper.

Nematollah Jaafari contributed to the writing of the paper.

Remy Boussageon conceived the study and analysed the data.


  1. 1.
    Sloane PD (2001) Dizziness: state of the science. Annals of Internal Medicine 134:823. CrossRefGoogle Scholar
  2. 2.
    Adams RD, Victor M, Ropper AH (1997) Principles of neurology, 6th edn. McGraw-Hill, Health Professions, pp300–1Google Scholar
  3. 3.
    Hanley K, O’ Dowd T (2002) Symptoms of vertigo in general practice: a prospective study of diagnosis. Br J Gen Pract 52: 809–812Google Scholar
  4. 4.
    Brandt T, Dieterich M, Strupp M (2013) Vertigo and dizziness: common complaints, 2nd edn. Springer-Verlag, LondonCrossRefGoogle Scholar
  5. 5.
    Karatas M (2008) Central vertigo and dizziness: epidemiology, differential diagnosis, and common causes. The Neurologist 14:355. CrossRefGoogle Scholar
  6. 6.
    Royl G, Ploner CJ, Möckel M, Leithner C (2010) Neurological chief complaints in an emergency room. Nervenarzt 81:1226–1230. CrossRefGoogle Scholar
  7. 7.
    Sloane PD (1989) Dizziness in primary care. Results from the National Ambulatory Medical Care Survey. J Fam Pract 29:33–38Google Scholar
  8. 8.
    Corrales CE, Bhattacharyya N (2016) Dizziness and death: an imbalance in mortality. The Laryngoscope 126:2134–2136 CrossRefGoogle Scholar
  9. 9.
    Chawla N, Olshaker JS (2006) Diagnosis and management of dizziness and vertigo. Med Clin North Am 90:291–304. CrossRefGoogle Scholar
  10. 10.
    Neuhauser HK, von Brevern M, Radtke A, Lezius F, Feldmann M, Ziese T et al (2005) Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology 65(6):898–904. CrossRefGoogle Scholar
  11. 11.
    Neuhauser HK (2016) Chapter 5 - the epidemiology of dizziness and vertigo. In: Furman JM, Lempert T (eds) Handbook of Clinical Neurology. Elsevier, pp 67–82Google Scholar
  12. 12.
    Rieger A, Mansmann U, Maier W et al (2014) Management of patients with the cardinal symptom dizziness or vertigo. Gesundheitswesen 76:e32–e38. Google Scholar
  13. 13.
    Kroenke K, Lucas CA, Rosenberg ML, Scherokman B, Herbers JE, Wehrle PA, et al. (1992) Causes of persistent dizziness: a prospective study of 100 patients in ambulatory care. Ann Intern Med 117:898–904.
  14. 14.
    Neuzil E, Ravaine S, Cousse H (2002) La N-acetyl-DL-leucine, médicament symptomatique des états vertigineux. Bulletin de la société de pharmacie de Bordeaux 141:15–38Google Scholar
  15. 15.
    Vibert N, Vidal PP (2001) In vitro effects of acetyl-DL-leucine (Tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci 13:73548. CrossRefGoogle Scholar
  16. 16.
    Ferber-Viart C, Dubreuil C, Vidal PP (2009) Effects of acetyl-DL-leucine in vestibular patients: a clinical study following neurotomy and labyrinthectomy. Audiol Neuro-otol 14:1725. CrossRefGoogle Scholar
  17. 17.
    Becker-Bense S, Feuerecker R, Xiong G et al (2015) P37. Effects of acetyl-dl-leucine on the cerebral activation pattern in cerebellar ataxia (FDG-PET study). Clinical Neurophysiology 126:e115. CrossRefGoogle Scholar
  18. 18.
    Commission de la Transparence HAS – avis du 6 juillet 2011: Tanganil®. Accessed 19 november 2016.
  19. 19.
    Commission de la Transparence HAS – avis du 9 novembre 2016: Tanganil®. Accessed 1st december 2016Google Scholar
  20. 20.
    Medic’AM (2018) Données mensuelles et annuelles sur les médicaments remboursés par l'Assurance Maladie en 2017. Ameli. Accessed 1st october 2018Google Scholar
  21. 21.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. CrossRefGoogle Scholar
  22. 22.
    Chinellato F (1960) Experimental research on the behavior of vestibular function after the administration of certain drugs. II. Acetyl-DL-leucine. Boll Soc Ital Biol Sper 36:112830Google Scholar
  23. 23.
    Günther L, Beck R, Xiong G, Potschka H, Jahn K, Bartenstein P et al (2015) N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus. PLoS ONE 10:e0120891 CrossRefGoogle Scholar
  24. 24.
    Platt F, Strupp M (2016) An anecdotal report by an Oxford basic neuroscientist: effects of acetyl-DL-leucine on cognitive function and mobility in the elderly. J Neurol 263:123940. CrossRefGoogle Scholar
  25. 25.
    Clément G, Deguine O, Bourg M, Pavy-LeTraon A (2007) Effects of vestibular training on motion sickness, nystagmus, and subjective vertical. J Vestib Res 17:22737Google Scholar
  26. 26.
    Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP et al (2013) Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol 260:255661. CrossRefGoogle Scholar
  27. 27.
    Schniepp R, Strupp M, Wuehr M, Jahn K, Dieterich M, Brandt T et al (2016) Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series. Cerebellum Ataxias 3(8).
  28. 28.
    Bremova T, Malinová V, Amraoui Y et al (2015) Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology 85:1368–1375. CrossRefGoogle Scholar
  29. 29.
    Feil K, Adrion C, Teufel J et al (2017) Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial. BMC Neurol 17(7)
  30. 30.
    Feil K, Bremova T, Muth C et al (2016) Update on the pharmacotherapy of cerebellar ataxia and nystagmus. The Cerebellum 15:38–42. CrossRefGoogle Scholar
  31. 31.
    Hussain K, Schilder AG (2016) Betahistine for symptoms of vertigo. Cochrane Database Syst Rev 21(6):CD010696. Google Scholar
  32. 32.
    Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M, BEMED Study Group (2016) Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 352:h6816.
  33. 33.
    Fishman JM, Burgess C, Waddell A (2011) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev CD008607.
  34. 34.
    McDonnell MN, Hillier SL (2015) Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev 1:CD005397. Google Scholar
  35. 35.
    Hilton MP, Pinder DK (2014) The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo. Cochrane Database Syst Rev 12:CD003162. Google Scholar
  36. 36.
    Boussageon R, Foucher E, Huas C (2017) Connaissances des médecins généralistes sur l’efficacité de sept médicaments courants : Enquête par questionnaire. Médecine 13:205–210Google Scholar
  37. 37.
    ANSM. Notice patient Tanganil. ANSM. 2018. Accessed 15 december 2018
  38. 38.
    Louhiala P, Hemilä H, Puustinen R (2015) Impure placebo is a useless concept. Theor Med Bioeth. 36(4):279–289. CrossRefGoogle Scholar
  39. 39.
    Hasham I (2010) Family physicians believe the placebo effect is therapeutic but often use real drugs as placebos. Family Medicine 42:636–42Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Paul Vanderkam
    • 1
    • 2
    Email author
  • Clara Blanchard
    • 1
  • Florian Naudet
    • 3
  • Denis Pouchain
    • 4
  • Helene Vaillant Roussel
    • 5
  • Marie Christine Perault-Pochat
    • 6
  • Nematollah Jaafari
    • 7
  • Rémy Boussageon
    • 8
  1. 1.Department of General MedicineUniversity of PoitiersPoitiers Cedex 9France
  2. 2.Clinical Research UnitHenri Laborit HospitalPoitiersFrance
  3. 3.CHU Rennes, Inserm, CIC 1414 (Clinical Center of Investigation, Rennes)Univ RennesRennesFrance
  4. 4.Department of General MedicineUniversity of ToursTours Cedex 1France
  5. 5.Department of General Medicine and UPU ACCePPTUniversity of Auvergne Clermont-Ferrand Cedex 1Clermont-Ferrand Cedex 1France
  6. 6.Clinical Pharmacology and Awareness DepartmentUniversity Hospital of PoitiersPoitiers CedexFrance
  7. 7.CNRS 3557, CIC-P 1402 and Clinical Research UnitHenri Laborit HospitalPoitiersFrance
  8. 8.University College of General Medicine and UMR 5558, Laboratoire de Biométrie et Biologie EvolutiveClaude-Bernard Lyon 1 University, CNRSLyonFrance

Personalised recommendations